Kura Oncology to Participate in Cantor Global Healthcare Conference
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in the upcoming Cantor Global Healthcare Conference in New York. The company's President and CEO, Troy Wilson, Ph.D., J.D., is set to take part in a fireside chat on September 17, 2024, at 1:20 p.m. ET / 10:20 a.m. PT.
Interested parties can access a live audio webcast of the fireside chat through the investor section of Kura's website at www.kuraoncology.com. An archived replay will also be available after the live event concludes. This conference participation provides an opportunity for Kura Oncology to showcase its progress and engage with the healthcare investment community.
Kura Oncology (Nasdaq: KURA), un'azienda biofarmaceutica in fase clinica focalizzata su medicinali di precisione per il trattamento del cancro, ha annunciato la sua partecipazione alla prossima Cantor Global Healthcare Conference a New York. Il Presidente e CEO dell'azienda, Troy Wilson, Ph.D., J.D., parteciperà a una conversazione informale il 17 settembre 2024, alle 13:20 ET / 10:20 PT.
Le parti interessate possono accedere a una trasmissione audio live della conversazione attraverso la sezione investitori del sito web di Kura all'indirizzo www.kuraoncology.com. Sarà inoltre disponibile una registrazione archiviata dopo la conclusione dell'evento dal vivo. Questa partecipazione alla conferenza offre a Kura Oncology l'opportunità di mostrare i suoi progressi e interagire con la comunità degli investimenti nel settore sanitario.
Kura Oncology (Nasdaq: KURA), una empresa biofarmacéutica en etapa clínica centrada en medicamentos de precisión para el tratamiento del cáncer, ha anunciado su participación en la próxima Cantor Global Healthcare Conference en Nueva York. El Presidente y CEO de la empresa, Troy Wilson, Ph.D., J.D., participará en una charla informal el 17 de septiembre de 2024, a las 1:20 p.m. ET / 10:20 a.m. PT.
Las partes interesadas pueden acceder a una transmisión de audio en vivo de la charla a través de la sección de inversores del sitio web de Kura en www.kuraoncology.com. También estará disponible una repetición archivada después de que concluya el evento en vivo. La participación en esta conferencia brinda a Kura Oncology la oportunidad de mostrar su progreso y relacionarse con la comunidad de inversión en salud.
Kura Oncology (Nasdaq: KURA)는 암 치료를 위한 정밀 의약품에 중점을 둔 임상 단계의 생물 의약품 회사로, 뉴욕에서 열리는 Cantor Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Troy Wilson, Ph.D., J.D.가 2024년 9월 17일 오후 1:20 ET / 오전 10:20 PT에 진행되는 간담회에 참가할 예정입니다.
관심 있는 분들은 Kura 웹사이트의 투자자 섹션을 통해 간담회 생방송 오디오 웹캐스트에 접속할 수 있습니다. 생방송 종료 후 아카이브 재생도 제공될 예정입니다. 이번 컨퍼런스 참여는 Kura Oncology가 자신의 발전을 보여주고 의료 투자 커뮤니티와 소통할 기회를 제공합니다.
Kura Oncology (Nasdaq: KURA), une entreprise biopharmaceutique au stade clinique axée sur les médicaments de précision pour le traitement du cancer, a annoncé sa participation à la prochaine Cantor Global Healthcare Conference à New York. Le président et CEO de l'entreprise, Troy Wilson, Ph.D., J.D., participera à une discussion informelle le 17 septembre 2024, à 13h20 ET / 10h20 PT.
Les parties intéressées peuvent accéder à un webinaire audio en direct de la discussion via la section investisseurs du site web de Kura à l'adresse www.kuraoncology.com. Un enregistrement archivé sera également disponible après la fin de l'événement en direct. La participation à cette conférence offre à Kura Oncology l'occasion de présenter ses progrès et d'interagir avec la communauté d'investissement en santé.
Kura Oncology (Nasdaq: KURA), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf präzisionsmedizinische Ansätze zur Krebsbehandlung konzentriert, hat seine Teilnahme an der bevorstehenden Cantor Global Healthcare Conference in New York bekannt gegeben. Der President und CEO des Unternehmens, Troy Wilson, Ph.D., J.D., wird am 17. September 2024 um 13:20 Uhr ET / 10:20 Uhr PT an einem informellen Gespräch teilnehmen.
Interessierte können über den Investorenbereich der Kura-Website unter www.kuraoncology.com auf einen Live-Audio-Webcast des Gesprächs zugreifen. Eine archivierte Wiedergabe wird ebenfalls nach Abschluss der Live-Veranstaltung verfügbar sein. Die Teilnahme an dieser Konferenz bietet Kura Oncology die Möglichkeit, seine Fortschritte zu präsentieren und mit der Gesundheitsinvestitionsgemeinschaft in Kontakt zu treten.
- None.
- None.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming Cantor Global Healthcare Conference being held in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 1:20 p.m. ET / 10:20 a.m. PT on September 17, 2024.
A live audio webcast of the fireside chat will be available in the investor section of Kura’s website at www.kuraoncology.com with an archived replay available following the live event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor (FTI), in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
FAQ
When is Kura Oncology (KURA) participating in the Cantor Global Healthcare Conference?
What time is Troy Wilson's fireside chat at the Cantor Global Healthcare Conference?
How can investors access Kura Oncology's (KURA) fireside chat at the Cantor conference?
Will there be a replay available of Kura Oncology's (KURA) presentation at the Cantor Global Healthcare Conference?
